Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

310 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR, O'dorisio TM. Warner RR, et al. Semin Nucl Med. 2002 Apr;32(2):79-83. doi: 10.1053/snuc.2002.31020. Semin Nucl Med. 2002. PMID: 11965602 Review.
Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, Ellison EC, O'Dorisio MS. Olsen JO, et al. Semin Nucl Med. 1995 Jul;25(3):251-61. doi: 10.1016/s0001-2998(95)80014-x. Semin Nucl Med. 1995. PMID: 7570044 Review.
Influence of isotope dose on somatostatin receptor imaging: when less is better.
Schirmer TP, O'Dorisio TM, Olsen JO, Hinkle GH, O'Dorisio MS, Schirmer WJ. Schirmer TP, et al. Semin Oncol. 1994 Oct;21(5 Suppl 13):51-5. Semin Oncol. 1994. PMID: 7992082 No abstract available.
Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. Menda Y, et al. J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2. J Nucl Med. 2017. PMID: 28153957 Free PMC article. Clinical Trial.
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Kwekkeboom DJ, et al. J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. J Nucl Med. 2005. PMID: 15653653 Review.
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M, Ali M, Roys J, Wolin EM, O╩╝Dorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Hamiditabar M, et al. Clin Nucl Med. 2017 Jun;42(6):436-443. doi: 10.1097/RLU.0000000000001629. Clin Nucl Med. 2017. PMID: 28263217
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. Strosberg JR, et al. Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. Pancreas. 2017. PMID: 28609356 Free PMC article. Review.
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Menda Y, et al. J Nucl Med. 2010 Oct;51(10):1524-31. doi: 10.2967/jnumed.110.075226. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847174 Free PMC article. Clinical Trial.
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
Bushnell D, O'Dorisio T, Menda Y, Carlisle T, Zehr P, Connolly M, Karwal M, Miller S, Parker S, Bouterfa H. Bushnell D, et al. J Nucl Med. 2003 Oct;44(10):1556-60. J Nucl Med. 2003. PMID: 14530466 Clinical Trial.
310 results
Jump to page
Feedback